secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001104659-25-109821
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics Q3 2025 cash $7.5M; raises $8M post-quarter, extends runway into Q1 2027
--------------------------------------------------------------------------------

- Cash and equivalents $7.5M at Sep 30; subsequent raises bring to $15.5M at Nov 10, funding ops into Q1 2027.
- Q3 R&D expense $2.6M (-7% YoY); G&A $1.9M (-18% YoY); workforce reduction implemented Sep 30.
- VIRAGE Phase 2b data for VCN-01 in metastatic PDAC presented at ESMO; planning Phase 3 discussions with EMA/FDA.
- Preclinical data for next-gen oncolytic virus VCN-12 showed improved cell killing and anti-tumor immunity vs VCN-01.
- Retinoblastoma Phase 2/3 trial design in progress; regulatory discussion expected H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925109821/0001104659-25-109821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925109821/tm2530928d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-109821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer